244 related articles for article (PubMed ID: 33682324)
1. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N; Kobayashi T; Otsuka R; Nio-Kobayashi J; Oshino T; Takahashi M; Imanishi S; Hashimoto A; Wada H; Seino KI
Cancer Immunol Immunother; 2023 Apr; 72(4):851-864. PubMed ID: 36104597
[TBL] [Abstract][Full Text] [Related]
4. Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.
Gupta N; Gaikwad S; Kaushik I; Wright SE; Markiewski MM; Srivastava SK
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068008
[TBL] [Abstract][Full Text] [Related]
5. Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
Zonneville J; Colligan S; Grant S; Miller A; Wallace P; Abrams SI; Bakin AV
Int J Cancer; 2020 Oct; 147(8):2279-2292. PubMed ID: 32452014
[TBL] [Abstract][Full Text] [Related]
6. Effective Host-Directed Therapy for Tuberculosis by Depletion of Myeloid-Derived Suppressor Cells and Related Cells Using a Diphtheria Toxin Fusion Protein.
Parveen S; Lun S; Urbanowski ME; Cardin M; Shen J; Murphy JR; Bishai WR
J Infect Dis; 2021 Dec; 224(11):1962-1972. PubMed ID: 33955457
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
8. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
9. Group 2 innate lymphoid cells promote TNBC lung metastasis via the IL-13-MDSC axis in a murine tumor model.
Zhao N; Zhu W; Wang J; Liu W; Kang L; Yu R; Liu B
Int Immunopharmacol; 2021 Oct; 99():107924. PubMed ID: 34217145
[TBL] [Abstract][Full Text] [Related]
10. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.
Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C
Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030
[TBL] [Abstract][Full Text] [Related]
11. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
12. Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model.
Zhang Q; Le K; Xu M; Zhou J; Xiao Y; Yang W; Jiang Y; Xi Z; Huang T
Int Immunopharmacol; 2019 Nov; 76():105864. PubMed ID: 31480004
[TBL] [Abstract][Full Text] [Related]
13. Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer.
Deng Y; Hu JC; He SH; Lou B; Ding TB; Yang JT; Mo MG; Ye DY; Zhou L; Jiang XC; Yu K; Dong JB
Acta Pharmacol Sin; 2021 Jan; 42(1):149-159. PubMed ID: 32451413
[TBL] [Abstract][Full Text] [Related]
14. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
Stravokefalou V; Stellas D; Karaliota S; Nagy BA; Valentin A; Bergamaschi C; Dimas K; Pavlakis GN
Front Immunol; 2022; 13():1014802. PubMed ID: 36713398
[TBL] [Abstract][Full Text] [Related]
15. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol attenuates TNBC lung metastasis by down-regulating PD-1 expression on pulmonary T cells and converting macrophages to M1 phenotype in a murine tumor model.
Han X; Zhao N; Zhu W; Wang J; Liu B; Teng Y
Cell Immunol; 2021 Oct; 368():104423. PubMed ID: 34399171
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
18. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
Fabian KP; Padget MR; Fujii R; Schlom J; Hodge JW
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602696
[TBL] [Abstract][Full Text] [Related]
19. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of LINS01 histamine H
Ospital IA; Táquez Delgado MA; Nicoud MB; Corrêa MF; Borges Fernandes GA; Andrade IW; Lauretta P; Martínez Vivot R; Comba MB; Zanardi MM; Speisky D; Uriburu JL; Fernandes JPS; Medina VA
Biomed Pharmacother; 2024 May; 174():116527. PubMed ID: 38579399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]